MESO insider trading
NasdaqGS HealthcareMESOBLAST LTD — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About MESOBLAST LTD
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Company website: www.mesoblast.com
MESO insider activity at a glance
FilingIQ has scored 30 insider transactions for MESO since Apr 4, 2026. The most recent filing in our index is dated Apr 10, 2026.
Across the full history, 30 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MESO insider trades is 50.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MESO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for MESO?
- FilingIQ tracks 30 Form 4 insider transactions for MESO (MESOBLAST LTD), covering filings from Apr 4, 2026 onwards. 30 of those were filed in the last 90 days.
- Are MESO insiders net buyers or net sellers?
- Across the full Form 4 history for MESO, 30 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MESO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is MESO in?
- MESOBLAST LTD (MESO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.15B.
Methodology & sources
Every MESO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.